

# Mahendra P Deonarain

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3801602/publications.pdf>

Version: 2024-02-01

21  
papers

740  
citations

623734

14  
h-index

752698

20  
g-index

24  
all docs

24  
docs citations

24  
times ranked

1148  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibodies targeting cancer stem cells: A new paradigm in immunotherapy?. <i>MAbs</i> , 2009, 1, 12-25.	5.2	130
2	Targeted photodynamic therapy with multiply-loaded recombinant antibody fragments. <i>International Journal of Cancer</i> , 2008, 122, 1155-1163.	5.1	75
3	Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?. <i>Antibodies</i> , 2018, 7, 16.	2.5	64
4	Emerging formats for next-generation antibody drug conjugates. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 463-481.	5.0	62
5	Modulation of Antibody Pharmacokinetics by Chemical Polysialylation. <i>Bioconjugate Chemistry</i> , 2008, 19, 643-650.	3.6	58
6	Fluorescence characterisation of multiply-loaded anti-HER2 single chain Fv-photosensitizer conjugates suitable for photodynamic therapy. <i>Photochemical and Photobiological Sciences</i> , 2007, 6, 933-939.	2.9	46
7	Novel photosensitisers derived from pyropheophorbide-a: uptake by cells and photodynamic efficiency in vitro. <i>Photochemical and Photobiological Sciences</i> , 2010, 9, 1033-1041.	2.9	45
8	Modulating antibody pharmacokinetics using hydrophilic polymers. <i>Expert Opinion on Drug Delivery</i> , 2011, 8, 1221-1236.	5.0	38
9	Antibody-Directed Phototherapy (ADP). <i>Antibodies</i> , 2013, 2, 270-305.	2.5	35
10	Recombinant antibodies for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1123-1141.	3.1	27
11	Development of Photodynamic Antimicrobial Chemotherapy (PACT) for <i>Clostridium difficile</i> . <i>PLoS ONE</i> , 2015, 10, e0135039.	2.5	23
12	Upregulation of mucin glycoprotein MUC1 in the progression to esophageal adenocarcinoma and therapeutic potential with a targeted photoactive antibody-drug conjugate. <i>Oncotarget</i> , 2017, 8, 25080-25096.	1.8	21
13	Miniaturised antibody-drug conjugates for solid tumours?. <i>Drug Discovery Today: Technologies</i> , 2018, 30, 47-53.	4.0	19
14	Phage display of chelating recombinant antibody libraries. <i>Molecular Immunology</i> , 2007, 44, 2860-2869.	2.2	16
15	Current strategies for the discovery and bioconjugation of smaller, targetable drug conjugates tailored for solid tumor therapy. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 613-624.	5.0	16
16	A recombinant cytotoxic chimera based on mammalian deoxyribonuclease-I. , 2000, 86, 561-569.		15
17	Tackling solid tumour therapy with small-format drug conjugates. <i>Antibody Therapeutics</i> , 2020, 3, 237-245.	1.9	14
18	Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression. <i>Oncotarget</i> , 2018, 9, 22945-22959.	1.8	11

#	ARTICLE	IF	CITATIONS
19	Ligand-targeted receptor-mediated vectors for gene delivery. Expert Opinion on Therapeutic Patents, 1998, 8, 53-69.	5.0	10
20	Production and binding analyses of a humanised scFv against a cryptic epitope on tumour-associated fibronectin. Protein Expression and Purification, 2013, 88, 157-163.	1.3	4
21	Abstract 2901: Gastric cancer antibody fragment drug-conjugates (FDCs): From concept to clinical development. , 2020, , .		2